Study Examines Antibody Response to COVID-19 Vaccination in Patients with Kidney Failure

American Society of Nephrology (ASN)

Highlight

  • Most patients with kidney failure who were undergoing hemodialysis developed a positive antibody response after being vaccinated for COVID-19, but their response was lower than that of individuals without kidney disease.

Newswise — Washington, DC (April 6, 2021) — In a recent study, most patients with kidney failure who were undergoing hemodialysis developed a substantial antibody response following the vaccination with the Pfizer-BioNTech vaccine against COVID-19, but it was significantly lower than that of individuals without kidney disease. The findings will appear in an upcoming issue of CJASN.

Individuals with kidney failure who are receiving dialysis treatments have a higher risk of experiencing severe COVDI-19 if they become infected with the virus that causes the disease. Therefore, vaccination may be especially important for these patients; however, they also tend to mount reduced immune responses against infections and vaccinations. To assess their responses to COVID-19 vaccination, a team led by Moshe Shashar MD (Laniado Hospital and Tel-Aviv Medical Center, Israel) compared antibody responses following vaccination with the Pfizer-BioNTech vaccine in 56 patients on maintenance hemodialysis vs. 95 healthcare workers.

All of the healthcare workers developed a positive antibody response to the virus that causes COVID-19, compared with 96% of participants in the dialysis group. The average antibody levels in patients on dialysis were significantly lower than those among healthcare workers. Also, there was a significant inverse correlation of age and antibody levels in both groups.

Although the findings are preliminary and warrant further clarifications and verifications, they suggest that COVD-19 vaccination doses and schedules should be reconsidered for individuals with kidney failure who are on dialysis.

“I believe our findings should encourage patients with kidney failure treated with dialysis to be vaccinated as soon as vaccination becomes available for them, while we as a care givers should explore ways to enhance its efficacy in our patients,” said Dr. Shashar.

Study co-authors include Ayelet Grupper, MD, Nechama Sharon, MD, Talya Finn, MBBS, Regev Cohen, MD, Meital Israel, MA, Amir Agbaria, MD, Yoav Rechavi BMedsc, Idit F. Schwartz, MD, Doron Schwartz, MD, and Yonatan Lellouch, PhD.

Disclosures: A. Grupper and I.F. Schwartz report employment with Tel-Aviv Medical Center. M. Israel and Y. Rechavi report employment with Laniado hospital. D. Schwartz reports employment with Sourasky Medical Center. The remaining authors have nothing to disclose.

The article, titled “Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis,” will appear online at http://cjasn.asnjournals.org/ on April 6, 2021, doi: 10.2215/CJN.03500321.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org.

 

# # #

 

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 5833
Newswise: Biophysical Study Sheds Light on Potentially Druggable Process of SARS-CoV-2 Replication
Released: 16-Jun-2021 12:50 PM EDT
Biophysical Study Sheds Light on Potentially Druggable Process of SARS-CoV-2 Replication
National Institute of Biomedical Imaging and Bioengineering

This study investigates how the nucleocapsid protein, or N protein, of the SARS-CoV-2 virus packages the viral genome.

Newswise: ‘Wonder material’ can be used to detect COVID-19 quickly, accurately
Released: 16-Jun-2021 11:55 AM EDT
‘Wonder material’ can be used to detect COVID-19 quickly, accurately
University of Illinois at Chicago

Researchers at the University of Illinois Chicago have successfully used graphene — one of the strongest, thinnest known materials — to detect the SARS-CoV-2 virus in laboratory experiments.

Newswise: UCLA-led Research Finds Connections Between Air Quality and COVID Vulnerability
Released: 16-Jun-2021 11:05 AM EDT
UCLA-led Research Finds Connections Between Air Quality and COVID Vulnerability
UCLA Fielding School of Public Health

Even as governments across the United States consider lifting mask mandates and relaxing preventative measures as vaccination numbers creep up, new research from a UCLA-led team has found that such basic techniques significantly reduce the risk of getting COVID-19. In addition, the research found that U.S. counties with higher exposures to poor air quality, historically, saw higher county-level COVID-19 mortality rates in 2020.

Newswise: Story Tips from Johns Hopkins Experts on COVID-19
Released: 16-Jun-2021 11:00 AM EDT
Story Tips from Johns Hopkins Experts on COVID-19
Johns Hopkins Medicine

NEWS STORIES IN THIS ISSUE: - Stressed About “Returning to Normal”? Here Are Tips to Ease Into the Transition - Be Your Brother’s Keeper: Steps for Faith-Based Communities to Reopen Safely

Newswise: Virtual Event For June 17, 11AM EDT: COVID-19 Vaccines and Male Fertility
Released: 16-Jun-2021 8:55 AM EDT
Virtual Event For June 17, 11AM EDT: COVID-19 Vaccines and Male Fertility
Newswise

This upcoming JAMA-published study examined whether the COVID-19 vaccine impacts male fertility.

Released: 16-Jun-2021 8:00 AM EDT
Two COVID-19 Vaccines Show Safety, Strong Immunity in Infant Model
University of North Carolina School of Medicine

The Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

access_time Embargo lifts in 2 days
Embargo will expire: 17-Jun-2021 5:00 AM EDT Released to reporters: 16-Jun-2021 5:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 17-Jun-2021 5:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Data and Safety Review Board Reports How it Monitored the COVID-19 Vaccine Trials
Released: 15-Jun-2021 2:55 PM EDT
Data and Safety Review Board Reports How it Monitored the COVID-19 Vaccine Trials
University of Alabama at Birmingham

Evaluation of three vaccine candidates during the COVID-19 pandemic fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.

Released: 15-Jun-2021 1:55 PM EDT
NCCN Policy Summit Explores How COVID-19 Pandemic Can Lead to Improvements in Cancer Care
National Comprehensive Cancer Network® (NCCN®)

NCCN Policy Summit examines the impact of the past year on oncology policy in the U.S., such as resuming recommended screening and clinical trials, applying health innovations from the COVID-19 pandemic to cancer treatment, and addressing systemic inequalities that lead to disparities in outcomes.


Showing results

110 of 5833

close
1.48709